1. Academic Validation
  2. Naringenin inhibits autophagy and epithelial-mesenchymal transition of human lens epithelial cells by regulating the Smad2/3 pathway

Naringenin inhibits autophagy and epithelial-mesenchymal transition of human lens epithelial cells by regulating the Smad2/3 pathway

  • Drug Dev Res. 2022 Apr;83(2):389-396. doi: 10.1002/ddr.21868.
Qingnan Li 1 Shuang Liu 1 Guang Yang 1 Mingming Li 2 Peng Qiao 3 Qiang Xue 4
Affiliations

Affiliations

  • 1 Department of Ophthalmology, Beijing Jishuitan Hospital, Beijing, China.
  • 2 Department of Ophthalmology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
  • 3 Department of Ophthalmology, 3201 Hospital, Hanzhong, Shanxi, China.
  • 4 Department of Geriatrics, Beijing Jishuitan Hospital, Beijing, China.
Abstract

Cataract is the number one cause of blindness in the world. Fibrosis of the lens is the main cause of cataract. Pathological epithelial-mesenchymal transition (EMT) plays an important role in the development of fibrotic cataract. Inhibition of EMT may be an effective treatment for fibrosis of lens epithelial cells. Naringin (NRG) is one of the major citrus Flavonoids, which has many pharmacological properties, including anti-inflammatory and cardioprotective. However, the effect of NRG on cataract induced by abnormal fibrosis of LECs is not clear. Herein, we found NRG inhibited transforming growth factor β2 (TGFβ2)-induced SRA01/04 cell viability. Additionally, NRG inhibited TGFβ2-induced cell migration and EMT. We further noticed that NRG inhibited Autophagy and SMAD2/3 phosphorylation in LECs. We therefore thought Naringenin inhibited Autophagy and EMT of human LECs by regulating the SMAD2/3 pathway. NRG could therefore serve as a promising drug for cataract treatment.

Keywords

Smad2/3 pathway; autophagy; cataract; epithelial-mesenchymal transition; naringin.

Figures
Products